✦ LIBER ✦

Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer

✍ Scribed by Peter C. Kohler; John T. Hamm; Valerie J. Wiebe; Michael W. DeGregorio; Irving Shemano; Douglass C. Tormey

Publisher: Springer US
Year: 1990
Tongue: English
Weight: 590 KB
Volume: 16
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01807140

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical and pharmacokinetics st

Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer

✍ James Bishop; Robin Murray; Lorraine Webster; Paula Pitt; Kerrie Stokes; Anne Fe 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 598 KB

Pharmacokinetics of toremifene and its m

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

✍ Valerie J. Wiebe; Christopher C. Benz; Irving Shemano; Timothy B. Cadman; Michae 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 433 KB

Phase I study of oxaliplatin in patients

Phase I study of oxaliplatin in patients with advanced cancer

✍ Jean Marc Extra; Marc Espie; Fabien Calvo; Christophe Ferme; Laurent Mignot; Mic 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 480 KB

A pharmacokinetic and tolerance study of

A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis

✍ Dr P. E. O. Williams; H. A. Bird; S. Minty; P. S. Helliwell; G. J. Muirhead; J. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB

Romazarit is a new drug for which animal pharmacology suggests a disease-modifying action in rheumatoid arthritis (RA). These animal studies predict that plasma romazarit concentrations within the range 50-100 mg I-' may be required for efficacy in the clinic. Therefore, a pharmacokinetic study was

Pharmacokinetics, safety, and tolerabili

Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction

✍ J. L. Hinson; I. D. Hind; D. J. Weidler 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 513 KB

Phase I and pharmacologic evaluation of

Phase I and pharmacologic evaluation of nafazatrom in patients with cancer

✍ Charles D. Haas; Laurence H. Baker; Llewelyn J. Evans 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 306 KB

Nafazatrom was evaluated in escalating daily oral doses ranging from 0.25 to 8.0 g/m 2 without producing significant toxicities. Malabsorption proved dose limiting at 8.0 g/m 2 as a single daily dose, but splitting the same total dose into two or four doses circumvented this problem. Doses of 2.0 g/